Lyell Immunopharma, Inc.
LYEL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $296,672 | $130,770 | $158,763 | $170,585 |
| - Cash | $123,575 | $98,804 | $120,328 | $105,597 |
| + Debt | $44,285 | $55,107 | $57,089 | $58,968 |
| Enterprise Value | $217,382 | $87,073 | $95,524 | $123,956 |
| Revenue | $15 | $8 | $7 | $11 |
| % Growth | 87.5% | 14.3% | -36.4% | – |
| Gross Profit | $15 | $8 | $7 | $11 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$36,280 | -$42,562 | -$53,926 | -$57,640 |
| % Margin | -241,866.7% | -532,025% | -770,371.4% | -524,000% |
| Net Income | -$38,846 | -$42,684 | -$52,195 | -$191,935 |
| % Margin | -258,973.3% | -533,550% | -745,642.9% | -1,744,863.6% |
| EPS Diluted | -2.13 | -2.89 | -0.18 | -0.72 |
| % Growth | 26.3% | -1,505.6% | 75% | – |
| Operating Cash Flow | -$28,577 | -$34,458 | -$54,738 | -$47,242 |
| Capital Expenditures | -$62 | -$168 | -$246 | -$44 |
| Free Cash Flow | -$28,639 | -$34,626 | -$54,984 | -$47,286 |